Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | AMLX |
---|---|---|
09:32 ET | 10500 | 5.595 |
09:33 ET | 2423 | 5.66 |
09:35 ET | 7969 | 5.59 |
09:37 ET | 9983 | 5.53 |
09:39 ET | 8400 | 5.54 |
09:42 ET | 26178 | 5.52 |
09:44 ET | 14928 | 5.55 |
09:46 ET | 10416 | 5.62 |
09:48 ET | 1500 | 5.6095 |
09:50 ET | 4823 | 5.59 |
09:51 ET | 3365 | 5.59 |
09:53 ET | 565 | 5.5815 |
09:55 ET | 4287 | 5.59 |
09:57 ET | 530 | 5.618 |
10:00 ET | 1681 | 5.65 |
10:02 ET | 5234 | 5.71 |
10:04 ET | 1499 | 5.73 |
10:06 ET | 4451 | 5.68 |
10:08 ET | 2402 | 5.6712 |
10:09 ET | 733 | 5.69 |
10:11 ET | 2370 | 5.705 |
10:13 ET | 8930 | 5.72 |
10:15 ET | 7727 | 5.685 |
10:18 ET | 1141 | 5.675 |
10:20 ET | 1840 | 5.684 |
10:22 ET | 18089 | 5.72 |
10:24 ET | 6502 | 5.75 |
10:26 ET | 6676 | 5.73 |
10:27 ET | 2320 | 5.745 |
10:29 ET | 2000 | 5.745 |
10:31 ET | 13675 | 5.755 |
10:33 ET | 1390 | 5.755 |
10:36 ET | 5249 | 5.74 |
10:38 ET | 3848 | 5.75 |
10:40 ET | 4750 | 5.745 |
10:42 ET | 3498 | 5.73 |
10:44 ET | 500 | 5.735 |
10:45 ET | 8194 | 5.725 |
10:47 ET | 3064 | 5.715 |
10:49 ET | 1255 | 5.735 |
10:51 ET | 1300 | 5.735 |
10:54 ET | 2388 | 5.755 |
10:56 ET | 2017 | 5.745 |
10:58 ET | 993 | 5.74 |
11:00 ET | 1714 | 5.735 |
11:02 ET | 5327 | 5.71 |
11:03 ET | 1400 | 5.71 |
11:05 ET | 2672 | 5.71 |
11:07 ET | 300 | 5.695 |
11:09 ET | 2000 | 5.705 |
11:12 ET | 4847 | 5.705 |
11:14 ET | 800 | 5.705 |
11:16 ET | 23521 | 5.695 |
11:18 ET | 7220 | 5.695 |
11:20 ET | 2983 | 5.6841 |
11:21 ET | 1446 | 5.675 |
11:23 ET | 19102 | 5.705 |
11:25 ET | 1900 | 5.69 |
11:27 ET | 100 | 5.69 |
11:30 ET | 1400 | 5.69 |
11:34 ET | 2250 | 5.69 |
11:36 ET | 2200 | 5.685 |
11:38 ET | 1584 | 5.68 |
11:39 ET | 300 | 5.675 |
11:41 ET | 3500 | 5.6693 |
11:43 ET | 1635 | 5.68 |
11:45 ET | 3253 | 5.6599 |
11:48 ET | 7500 | 5.642 |
11:50 ET | 3036 | 5.645 |
11:52 ET | 416 | 5.635 |
11:54 ET | 2239 | 5.62 |
11:56 ET | 700 | 5.625 |
11:57 ET | 500 | 5.625 |
11:59 ET | 1400 | 5.63 |
12:01 ET | 1800 | 5.605 |
12:03 ET | 1500 | 5.61 |
12:06 ET | 2153 | 5.5901 |
12:08 ET | 18291 | 5.65 |
12:10 ET | 1970 | 5.665 |
12:12 ET | 4038 | 5.655 |
12:14 ET | 1900 | 5.655 |
12:15 ET | 500 | 5.655 |
12:17 ET | 200 | 5.655 |
12:19 ET | 400 | 5.655 |
12:21 ET | 800 | 5.66 |
12:24 ET | 780 | 5.6611 |
12:26 ET | 1200 | 5.66 |
12:28 ET | 300 | 5.665 |
12:30 ET | 3939 | 5.665 |
12:32 ET | 800 | 5.675 |
12:33 ET | 830 | 5.675 |
12:35 ET | 100 | 5.675 |
12:37 ET | 850 | 5.675 |
12:39 ET | 1800 | 5.695 |
12:42 ET | 2216 | 5.705 |
12:44 ET | 2390 | 5.705 |
12:46 ET | 2073 | 5.715 |
12:48 ET | 860 | 5.715 |
12:50 ET | 2380 | 5.711 |
12:51 ET | 4499 | 5.71 |
12:53 ET | 1942 | 5.7012 |
12:55 ET | 1069 | 5.705 |
12:57 ET | 4880 | 5.705 |
01:00 ET | 726 | 5.71 |
01:02 ET | 500 | 5.705 |
01:04 ET | 5900 | 5.675 |
01:06 ET | 1000 | 5.655 |
01:08 ET | 2026 | 5.655 |
01:09 ET | 700 | 5.65 |
01:11 ET | 2050 | 5.68 |
01:13 ET | 2200 | 5.695 |
01:15 ET | 1021 | 5.695 |
01:18 ET | 501 | 5.69 |
01:22 ET | 609 | 5.695 |
01:24 ET | 323 | 5.695 |
01:26 ET | 3200 | 5.725 |
01:27 ET | 526 | 5.745 |
01:29 ET | 2135 | 5.755 |
01:31 ET | 5618 | 5.765 |
01:33 ET | 1450 | 5.775 |
01:36 ET | 8689 | 5.7949 |
01:38 ET | 5658 | 5.775 |
01:40 ET | 3733 | 5.755 |
01:42 ET | 1599 | 5.7538 |
01:44 ET | 947 | 5.7599 |
01:45 ET | 1237 | 5.765 |
01:47 ET | 1667 | 5.765 |
01:49 ET | 2501 | 5.765 |
01:54 ET | 652 | 5.765 |
01:56 ET | 1668 | 5.76 |
01:58 ET | 3100 | 5.765 |
02:00 ET | 1487 | 5.7501 |
02:02 ET | 2000 | 5.77 |
02:03 ET | 200 | 5.76 |
02:05 ET | 1418 | 5.755 |
02:07 ET | 2900 | 5.745 |
02:09 ET | 6984 | 5.73 |
02:12 ET | 1569 | 5.72 |
02:14 ET | 1800 | 5.725 |
02:16 ET | 195 | 5.725 |
02:18 ET | 520 | 5.73 |
02:20 ET | 1688 | 5.7328 |
02:21 ET | 300 | 5.735 |
02:23 ET | 594 | 5.74 |
02:25 ET | 688 | 5.7415 |
02:27 ET | 1000 | 5.745 |
02:30 ET | 3377 | 5.7499 |
02:32 ET | 1024 | 5.735 |
02:34 ET | 1935 | 5.755 |
02:36 ET | 100 | 5.755 |
02:38 ET | 1571 | 5.765 |
02:39 ET | 4247 | 5.735 |
02:41 ET | 800 | 5.7328 |
02:43 ET | 700 | 5.72 |
02:45 ET | 100 | 5.725 |
02:48 ET | 100 | 5.725 |
02:50 ET | 2189 | 5.725 |
02:52 ET | 500 | 5.725 |
02:56 ET | 324 | 5.7288 |
02:57 ET | 1000 | 5.735 |
02:59 ET | 651 | 5.735 |
03:01 ET | 1233 | 5.75 |
03:03 ET | 9395 | 5.745 |
03:06 ET | 2596 | 5.745 |
03:08 ET | 1304 | 5.735 |
03:10 ET | 1429 | 5.745 |
03:12 ET | 9700 | 5.725 |
03:14 ET | 100 | 5.725 |
03:15 ET | 2333 | 5.7201 |
03:17 ET | 1161 | 5.735 |
03:19 ET | 2527 | 5.724 |
03:21 ET | 100 | 5.725 |
03:24 ET | 1725 | 5.715 |
03:26 ET | 1553 | 5.725 |
03:28 ET | 2302 | 5.725 |
03:30 ET | 400 | 5.725 |
03:32 ET | 2803 | 5.725 |
03:33 ET | 1398 | 5.725 |
03:35 ET | 1452 | 5.725 |
03:37 ET | 1650 | 5.715 |
03:39 ET | 1944 | 5.705 |
03:42 ET | 2800 | 5.715 |
03:44 ET | 2840 | 5.725 |
03:46 ET | 2220 | 5.7247 |
03:48 ET | 3020 | 5.715 |
03:50 ET | 4408 | 5.725 |
03:51 ET | 2401 | 5.725 |
03:53 ET | 8281 | 5.7 |
03:55 ET | 5860 | 5.694 |
03:57 ET | 6869 | 5.69 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Amylyx Pharmaceuticals Inc | 384.0M | -2.3x | --- |
Organogenesis Holdings Inc | 368.6M | -24.0x | --- |
Amarin Corporation PLC | 240.9M | -6.4x | --- |
Ironwood Pharmaceuticals Inc | 669.3M | 97.1x | --- |
Sinovac Biotech Ltd | 639.9M | -4.9x | --- |
Voyager Therapeutics Inc | 381.7M | 43.5x | --- |
Amylyx Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery and development of treatments for neurodegenerative diseases. The Company is focused on the development and commercialization of its product candidate: AMX0035 for the treatment of Wolfram syndrome and for the treatment of progressive supranuclear palsy, and AMX0114, the Company’s antisense oligonucleotide targeting calpain-2 for the treatment of amyotrophic lateral sclerosis (ALS). AMX0035 is a dual-unfolded protein response (UPR)-Bax apoptosis inhibitor composed of PB and TURSO (also known as TUDCA). The Company’s Avexitide is an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist that has been evaluated in five clinical trials for post-bariatric hypoglycemia (PBH) and has also been studied in congenital hyperinsulinism (HI), two indications characterized by hyperinsulinemic hypoglycemia.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $384.0M |
---|---|
Revenue (TTM) | $298.8M |
Shares Outstanding | 68.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-2.45 |
Book Value | $6.40 |
P/E Ratio | -2.3x |
Price/Sales (TTM) | 1.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -59.50% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.